Information Center
Dr. Wang Kai has joined Xinkanghe Biopharmaceuticals as Chief Medical Officer (CMO).
Release time:
2024-01-09 09:29
Beijing, Suzhou, January 9, 2024, Xinkanghe Bio announced with great fanfare the appointment of Dr. Wang Kai as the Chief Medical Officer (CMO) of the company, who will be fully responsible for the global clinical research of the company's ongoing projects. Dr. Wang officially joined today.
Dr. Wang has been deeply involved in the field of innovative drug clinical development for nearly 20 years, with rich experience in clinical research and development strategy formulation in treatment areas such as immunology, anti-infection, nephrology, and general internal medicine. Before joining Xinkanghe, Dr. Wang worked for many years at multinational pharmaceutical companies such as Johnson & Johnson, Bayer, and Eli Lilly, where he led the entire process from preclinical transition to post-marketing management as a medical leader, possessing over 17 years of team management experience while also serving in multiple functional team leader roles.
Before entering the industry, Dr. Wang had nearly 10 years of experience as a clinical physician and in research and teaching at medical schools, and he worked as a visiting scholar at Karolinska Institute in Sweden.
Dr. Wang stated: "Xinkanghe has been deeply engaged in the field of immunology for many years, with a strong research team and an innovative drug pipeline. Currently, key products have entered the clinical development stage. I am very pleased to join Xinkanghe and look forward to working with the team to facilitate the clinical translation of products and the expansion of indications, accelerate clinical development, and bring innovative treatment options to patients as soon as possible."
Mr. Wang Yaning, CEO of Xinkanghe Bio, stated: "We are very pleased to welcome Dr. Wang Kai. Xinkanghe Bio currently has multiple products at different stages of clinical research, especially in the development of new clinical indications. Dr. Wang's addition will further enhance the company's overall development capability from translational medicine to clinical research, promoting the innovative products and treatment methods of Xinkanghe to benefit global patients as soon as possible, meeting urgent clinical needs."
About Xinkanghe Bio-pharmaceuticals
Xinkanghe Bio-pharmaceuticals was established in 2015, founded by the internationally renowned immunologist Academician Dong Chen. The company is based on cutting-edge international immunology research, focusing on the development of macromolecular drugs for autoimmune diseases and immuno-oncology, committed to creating innovative drugs with independent intellectual property rights that originate from China and target the global market, providing patients with globally pioneering or best-in-class treatment options. The company adheres to the R&D philosophy of "innovation, precision, quality, and focus," combining solid basic science with translational medicine, possessing multiple innovative pipeline products and new indications with global independent intellectual property rights entering the clinical stage. Xinkanghe will continue to delve into the unmet clinical needs in the fields of inflammation/autoinflammatory diseases and tumor immunotherapy, and looks forward to deep cooperation with innovative pharmaceutical companies at home and abroad.
Medicine, Clinical
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com